Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304930 | 0.96 | F10 (0.69) | F10ATMSMN1; SMN2GAALMNA | |
| SCHEMBL6300303 | 0.90 | F10 (0.68) | F10ATMSMN1; SMN2GAALMNA | |
| SCHEMBL5734081 | 0.89 | F10 (0.67) | F10ATMSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5735220 | 0.88 | F10 (0.61) | F10ATMSMN1; SMN2GAALMNA | |
| SCHEMBL6299380 | 0.88 | F10 (0.66) | F10ATMSMN1; SMN2GAALMNA | |
| SCHEMBL6299384 | 0.88 | F10 (0.66) | F10ATMSMN1; SMN2GAALMNA | |
| SCHEMBL5193868 | 0.87 | ATM (0.71) | F10ATMSMN1; SMN2GAALMNA | |
| SCHEMBL6580076 | 0.87 | SMN1; SMN2 (0.59) | F10ATMSMN1; SMN2GAALMNA | |
| SCHEMBL6306092 | 0.86 | F10 (0.64) | F10ATMSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL6299391 | 0.86 | F10 (0.64) | F10ATMSMN1; SMN2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986551-B1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-6936610-B2 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-08-30 | — | — | US | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-0937048-B1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ASTRAZENECA AB (SE) | 2004-01-21 | — | — | EP | disclosed |
| EP-1358909-A1 | Heteroaryl-phenyl derivatives as factor xa inhibitors for use as antithrombotic and anticoagulant agents | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030195203-A1 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| US-6300330-B1 | BLOOD COAGULATION FACTOR X INHIBITORS AS ANTICOAGULANTS | ZENECA LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195203-A1 | Heterocyclic derivatives | F12, F11, F2 | F10 5/4885ATM 3746/4885SMN1; SMN2 3887/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | F10 19/4885ATM 2080/4885SMN1; SMN2 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.